Michael Chastain

3.7k total citations · 1 hit paper
20 papers, 1.8k citations indexed

About

Michael Chastain is a scholar working on Molecular Biology, Genetics and Virology. According to data from OpenAlex, Michael Chastain has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Virology. Recurrent topics in Michael Chastain's work include Virus-based gene therapy research (8 papers), HIV Research and Treatment (5 papers) and CAR-T cell therapy research (5 papers). Michael Chastain is often cited by papers focused on Virus-based gene therapy research (8 papers), HIV Research and Treatment (5 papers) and CAR-T cell therapy research (5 papers). Michael Chastain collaborates with scholars based in United States and Japan. Michael Chastain's co-authors include Ignacio Tinoco, Joseph D. Puglisi, Jacqueline R. Wyatt, Mohammed Milhem, Omid Hamid, Jeffrey Chou, David R. Minor, Abraham Anderson, Igor Puzanov and Kevin Gorski and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Michael Chastain

20 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

2016 435 citations Igor Puzanov, Mohammed Milhem et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Chastain United States	16	934	557	518	404	387	20	1.8k
Kerry M. Barnhart United States	21	981 1.1×	573 1.0×	228 0.4×	535 1.3×	213 0.6×	37	1.9k
James J. Crute United States	18	829 0.9×	663 1.2×	363 0.7×	430 1.1×	769 2.0×	25	2.1k
W.L. McClements United States	24	1000 1.1×	518 0.9×	194 0.4×	662 1.6×	780 2.0×	32	2.1k
Keith G. Gould United Kingdom	25	991 1.1×	1.4k 2.5×	334 0.6×	279 0.7×	416 1.1×	56	2.6k
Hua-Poo Su United States	20	583 0.6×	676 1.2×	337 0.7×	112 0.3×	380 1.0×	33	1.7k
Paul M. Loewenstein United States	19	2.0k 2.2×	391 0.7×	318 0.6×	957 2.4×	278 0.7×	45	2.7k
George E. Mark United States	22	861 0.9×	262 0.5×	208 0.4×	177 0.4×	216 0.6×	54	1.5k
Ellis van Liempt Netherlands	14	555 0.6×	1.0k 1.8×	188 0.4×	146 0.4×	292 0.8×	20	1.7k
Vladimir Slepushkin United States	25	1.7k 1.9×	332 0.6×	215 0.4×	1.0k 2.5×	428 1.1×	43	2.5k
Luisa Lozzi Italy	26	1.1k 1.1×	298 0.5×	144 0.3×	162 0.4×	220 0.6×	65	1.7k

Countries citing papers authored by Michael Chastain

Since Specialization

Citations

This map shows the geographic impact of Michael Chastain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Chastain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Chastain more than expected).

Fields of papers citing papers by Michael Chastain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Chastain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Chastain. The network helps show where Michael Chastain may publish in the future.

Co-authorship network of co-authors of Michael Chastain

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Chastain. A scholar is included among the top collaborators of Michael Chastain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Chastain. Michael Chastain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Puzanov, Igor, Mohammed Milhem, David R. Minor, et al.. (2016). Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology. 34(22). 2619–2626. 435 indexed citations breakdown →

Andtbacka, Robert H.I., et al.. (2015). Abstract B13: A phase 2, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs. surgery for resectable stage IIIB-IVM1a melanoma. Cancer Research. 75(14_Supplement). B13–B13. 2 indexed citations

Andtbacka, Robert Hans Ingemar, Michael Chastain, Li Ai, Mark Shilkrut, & Merrick I. Ross. (2015). Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).. Journal of Clinical Oncology. 33(15_suppl). TPS9094–TPS9094. 13 indexed citations

Puzanov, Igor, Mohammed Milhem, Robert Hans Ingemar Andtbacka, et al.. (2014). Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. Journal of Clinical Oncology. 32(15_suppl). 9029–9029. 69 indexed citations

Loboda, Andrey, Michael Nebozhyn, Jason P. Frazier, et al.. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics. 3(1). 26–26. 107 indexed citations

Simon, Adam, Danilo R. Casimiro, Adam C. Finnefrock, et al.. (2008). Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine. 26(40). 5202–5209. 15 indexed citations

Joyce, Joseph G., Isaac J. Krauss, Karen M. Grimm, et al.. (2008). An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proceedings of the National Academy of Sciences. 105(41). 15684–15689. 104 indexed citations

Krauss, Isaac J., Joseph G. Joyce, Adam C. Finnefrock, et al.. (2007). Fully Synthetic Carbohydrate HIV Antigens Designed on the Logic of the 2G12 Antibody. Journal of the American Chemical Society. 129(36). 11042–11044. 91 indexed citations

Baliga, Christopher, et al.. (2006). Vaccination of Mice with Replication-Defective Human Immunodeficiency Virus Induces Cellular and Humoral Immunity and Protects against Vaccinia Virus-gag Challenge. Molecular Therapy. 14(3). 432–441. 5 indexed citations

10.

Jiang, Fan, Xiaoping Liang, Melanie Horton, et al.. (2004). Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 22(23-24). 2993–3003. 275 indexed citations

11.

McKelvey, Troy W., A Tang, Andrew J. Bett, Danilo R. Casimiro, & Michael Chastain. (2004). T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Therapy. 11(9). 791–796. 35 indexed citations

12.

Casimiro, Danilo R., Andrew J. Bett, Tong‐Ming Fu, et al.. (2004). Heterologous Human Immunodeficiency Virus Type 1 Priming-Boosting Immunization Strategies Involving Replication-Defective Adenovirus and Poxvirus Vaccine Vectors. Journal of Virology. 78(20). 11434–11438. 81 indexed citations

13.

Casimiro, Danilo R., Aimin Tang, Helen C. Perry, et al.. (2002). Vaccine-Induced Immune Responses in Rodents and Nonhuman Primates by Use of a Humanized Human Immunodeficiency Virus Type 1 pol Gene. Journal of Virology. 76(1). 185–194. 34 indexed citations

14.

Chastain, Michael, Adam Simon, Keith A. Soper, et al.. (2001). Antigen levels and antibody titers after DNA vaccination. Journal of Pharmaceutical Sciences. 90(4). 474–484. 33 indexed citations

15.

Ulmer, Jeffrey B., Corrille M. DeWitt, Michael Chastain, et al.. (1999). Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 18(1-2). 18–28. 113 indexed citations

16.

Chastain, Michael & Ignacio Tinoco. (1993). Nucleoside triples from the group I intron. Biochemistry. 32(51). 14220–14228. 22 indexed citations

17.

Chastain, Michael & Ignacio Tinoco. (1992). Poly(rA) ioinos poly(rG) poly(rC) to form a tripie helix. Nucleic Acids Research. 20(2). 315–318. 18 indexed citations

18.

Chastain, Michael & Ignacio Tinoco. (1992). A base-triple structural domain in RNA. Biochemistry. 31(51). 12733–12741. 37 indexed citations

19.

Wyatt, Jacqueline R., Michael Chastain, & Joseph D. Puglisi. (1991). Synthesis and purification of large amounts of RNA oligonucleotides.. PubMed. 11(6). 764–9. 169 indexed citations

20.

Chastain, Michael & Ignacio Tinoco. (1991). Structural Elements in RNA. Progress in nucleic acid research and molecular biology. 41. 131–177. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact